Sino Biopharmaceutical’s invoX Pharma subsidiary does not anticipate a favorable outcome from the Committee on Foreign Investment of the United States, or CFIUS, review of its proposed deal to buy F-Star Therapeutics by the deadline of January 31, said Dealreporter, citing two sources, contacts tell The Fly.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on FSTX:
- F-Star Therapeutics Plunges as Sale Falters
- invoX Pharma and F-star Therapeutics issue Joint Statement
- F-star Therapeutics says invoX offer extended to January 17
- F-star says invoX extended offer, in further extension talks after CFIUS warning
- F-star Therapeutics presents clinical data on antitumor activity of FS222